Tango Therapeutics (TNGX) Operating Expenses (2020 - 2026)

Tango Therapeutics' Operating Expenses history runs 7 years deep, the most recent figure standing at $12.0 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 35.74% year-over-year to $12.0 million in Q1 2026; TTM through Mar 2026 was $137.7 million, a 40.84% decrease from a year earlier, with the FY2025 full-year figure at $173.7 million, down 7.46% from the prior year.
• Operating Expenses retreated to $12.0 million in Q1 2026 per TNGX's latest filing, from $41.9 million in the prior quarter.
• Across five years, Operating Expenses topped out at $167.1 million in Q4 2024 and bottomed at $7.5 million in Q3 2024.
• The 5-year median for Operating Expenses is $37.0 million (2022), against an average of $41.5 million.
• Biggest YoY gain for Operating Expenses was 429.08% in 2025; the steepest drop was 81.89% in 2025.
• Year by year, Operating Expenses stood at $37.0 million in 2022, then rose by 9.37% to $40.4 million in 2023, then surged by 313.07% to $167.1 million in 2024, then tumbled by 74.94% to $41.9 million in 2025, then plunged by 71.38% to $12.0 million in 2026.
• Per Business Quant, the three latest TNGX Operating Expenses figures stand at $12.0 million (Q1 2026), $41.9 million (Q4 2025), and $39.7 million (Q3 2025).